Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases.

Collazos, Julio; Esteban, Cristóbal; Fernández, A; Genollá, J

doi:10.1164/ajrccm.150.1.8025740

Cited by 23 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its half-life in serum is estimated to be approximately 30 h. 101 The αγ isoform is expressed in large amounts also in erythrocytes and in platelets, therefore it is important to separate blood cells from plasma or serum within 60 minutes from sample collection to prevent haemolysis of blood samples, which could lead to falsely elevated levels of gamma-enolase. 80 , 102 , 103 Falsely elevated serum levels of gamma-enolase might be also due to various noncancerous pathological causes 104 , such as benign pulmonary diseases 105 , renal failure 106 , brain injuries, seizures, stroke 38 , 107 , severe hypoglycaemia 108 , benign liver diseases 109 or systemic sclerosis. 110…”

Section: Gamma-enolase In Extracellular Fluids Of Cancer Patientsmentioning

confidence: 99%

Gamma-enolase: a well-known tumour marker, with a less-known role in cancer

Vizin

Kos

2015

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundGamma-enolase, known also as neuron-specific enolase (NSE), is an enzyme of the glycolytic pathway, which is expressed predominantly in neurons and cells of the neuroendocrine system. As a tumour marker it is used in diagnosis and prognosis of cancer; however, the mechanisms enrolling it in malignant progression remain elusive. As a cytoplasmic enzyme gamma-enolase is involved in increased aerobic glycolysis, the main source of energy in cancer cells, supporting cell proliferation. However, different cellular localisation at pathophysiological conditions, proposes other cellular engagements.ConclusionsThe C-terminal part of the molecule, which is not related to glycolytic pathway, was shown to promote survival of neuronal cells by regulating neuronal growth factor receptor dependent signalling pathways, resulting also in extensive actin cytoskeleton remodelling. This additional function could be important also in cancer cells either to protect cells from stressful conditions and therapeutic agents or to promote tumour cell migration and invasion. Gamma-enolase might therefore have a multifunctional role in cancer progression: it supports increased tumour cell metabolic demands, protects tumour cells from stressful conditions and promotes their invasion and migration.

show abstract

Section: Gamma-enolase In Extracellular Fluids Of Cancer Patientsmentioning

confidence: 99%

Gamma-enolase: a well-known tumour marker, with a less-known role in cancer

Vizin

Kos

2015

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…Inoue et al [ 11 ] have reported significantly higher NSE level in cerebrospinal fluid during bacterial meningitis. In addition, non-malignant inflammatory lung disorders have been reported to be associated with abnormal NSE serum concentration [ 12 , 13 ]. In a study from Collazos et al [ 12 ], 27.3% of all patients with active pulmonary TB had increased NSE concentration compared with 11.1% of all patients with overall benign pulmonary disease.…”

Section: Introductionmentioning

confidence: 99%

Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response

Nam

Jeong

Jang

et al. 2016

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims:It is not clear which tests are indicative of the activity and severity of tuberculosis (TB). This study aimed to investigate the predictive value of neuron-specific enolase (NSE) and to determine the origin of NSE in TB patients.Methods:A single-center retrospective analysis was conducted on newly diagnosed TB patients between January and December 2010. Patients were categorized into one of two disease groups (focal segmental or extensive) based on chest X-ray. Pre- and post-treatment NSE concentrations were evaluated. To determine the origin of serum NSE concentration, NSE staining was compared with macrophage-specific CD68 staining in lung tissues and with a tissue microarray using immunohistochemistry and immunofluorescence.Results:A total of 60 newly diagnosed TB patients were analyzed. In TB patients, NSE serum concentration was significantly increased and NSE level decreased after treatment (p < 0.001). In proportion to serum high-sensitivity C-reactive protein concentration, the mean serum concentration of NSE in the extensive group (25.12 ng/mL) was significantly higher than that in the focal segmental group (20.23 ng/mL, p = 0.04). Immunohistochemical staining revealed a large number of macrophages that stained positively for both NSE and CD68 in TB tissues. In addition, NSE signals mostly co-localized with CD68 signals in the tissue microarray of TB patients.Conclusions:Our results suggest that NSE may be a practical parameter that can be used to monitor TB activity and treatment response. Elevated serum NSE level originates, at least in part, from macrophages in granulomatous lesions.

show abstract

“…It is well-known in clinical practice that patients with tuberculosis (or HIV infection) often have increased NSE concentration. In general, patients with alveolar infiltrates or an interstitial pattern on chest X-ray had higher NSE levels than those with normal radiographs (36). Direct damage to the neural or neuroendocrine lung cells or a degree of local hypoxia are likely to play a role in the increase in NSE in these patients.…”

Section: Discussionmentioning

confidence: 88%

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay

Muley¹,

Ébert²,

Stieber³

et al. 2003

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

This international multicenter study was designed to evaluate the technical performance of the new doublemonoclonal, single-step Elecsys neuron-specific enolase (NSE) enzyme immunoassay (EIA) and to assess its utility as a sensitive and specific test for the diagnosis of small-cell lung cancer (SCLC). Intra-and interassay coefficients of variation, determined in five control or serum specimens in six laboratories, ranged from 0.7 to 5.3 (inter-laboratory median: 1.3%) and from 1.3 to 8.5 (inter-laboratory median: 3.4%), respectively. Laboratory-to-laboratory comparability was excellent with respect to recovery and inter-assay coefficients of variation. The test was linear between 0.0 and 320 ng/ml (highest measured concentration). There was a significant correlation between NSE concentrations measured using the Elecsys NSE and the established Cobas Core NSE EIA II in all subjects (n = 723) and in patients with lung cancer (n = 333). However, NSE concentrations were systematically lower (approximately 9%) with the Elecsys NSE than with the comparison test. Based on a specificity of 95% in comparison with the group suffering from benign lung diseases (n = 183), the cut-off value for the discrimination between malignant and benign conditions was set at 21.6 ng/ml. NSE was raised in 73.4% of SCLC patients (n = 188) and was significantly higher (p < 0.01) in extensive (87.8%) as opposed to limited disease (56.7%). NSE was also elevated in 16.0% of the cases with nonsmall cell lung cancer (NSCLC, n = 374). It is concluded that the Elecsys NSE EIA is a reliable and accurate di-

show abstract

Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases.

Cited by 23 publications

References 12 publications

Gamma-enolase: a well-known tumour marker, with a less-known role in cancer

Gamma-enolase: a well-known tumour marker, with a less-known role in cancer

Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response

Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay

Contact Info

Product

Resources

About